guest ::
| Home > Publications Database > Intrazerebrale Blutungen unter Plättchenaggregationshemmung und oraler Antikoagulation bei Patienten mit zerebraler Amyloidangiopathie. > print |
| Home > Publications Database > Intrazerebrale Blutungen unter Plättchenaggregationshemmung und oraler Antikoagulation bei Patienten mit zerebraler Amyloidangiopathie. > print |
| 001 | 162912 | ||
| 005 | 20240320115515.0 | ||
| 024 | 7 | _ | |a pmc:PMC9200694 |2 pmc |
| 024 | 7 | _ | |a 10.1007/s00115-021-01206-w |2 doi |
| 024 | 7 | _ | |a pmid:34652485 |2 pmid |
| 024 | 7 | _ | |a 0028-2804 |2 ISSN |
| 024 | 7 | _ | |a 1433-0407 |2 ISSN |
| 024 | 7 | _ | |a altmetric:115359607 |2 altmetric |
| 037 | _ | _ | |a DZNE-2021-01565 |
| 041 | _ | _ | |a German |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Haussmann, Robert |0 P:(DE-2719)9000458 |b 0 |e Corresponding author |u dzne |
| 245 | _ | _ | |a Intrazerebrale Blutungen unter Plättchenaggregationshemmung und oraler Antikoagulation bei Patienten mit zerebraler Amyloidangiopathie. |
| 260 | _ | _ | |a Heidelberg |c 2022 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1657544946_30472 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a (CC BY) |
| 520 | _ | _ | |a Oral anticoagulation in patients with cerebral amyloid angiopathy is a therapeutic challenge. The association of cerebral amyloid angiopathy with intracerebral hemorrhage, a high mortality of intracerebral hemorrhage especially under oral anticoagulation and the high risk of recurrent bleeding require a multidisciplinary approach and a thorough risk-benefit analysis. Vitamin K antagonists increase the risk of intracerebral bleeding and the accompanying mortality by 60% and should be avoided if possible or reserved for special clinical situations (e.g. mechanical aortic valve replacement). Treatment with novel oral anticoagulants and antiplatelet drugs also increases the risk of cerebral bleeding and therefore needs a thorough risk-benefit evaluation. An interventional left atrial appendage closure is a promising therapeutic option especially in patients with an absolute arrythmia with atrial fibrillation. Furthermore, other clinical implications in patients with cerebral amyloid angiopathy are the subject of this review of the literature, such as special characteristics after acute ischemic stroke and the necessary secondary prophylaxis, with previous intracerebral hemorrhage and in patients with cognitive deficits. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Cerebral amyloid angiopathy |2 Other |
| 650 | _ | 7 | |a Interventional left atrial appendage closure |2 Other |
| 650 | _ | 7 | |a Intracerebral hemorrhage |2 Other |
| 650 | _ | 7 | |a Oral anticoagulation |2 Other |
| 650 | _ | 7 | |a Platelet inhibition |2 Other |
| 650 | _ | 2 | |a Anticoagulants: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Atrial Fibrillation: complications |2 MeSH |
| 650 | _ | 2 | |a Atrial Fibrillation: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Cerebral Amyloid Angiopathy: complications |2 MeSH |
| 650 | _ | 2 | |a Cerebral Amyloid Angiopathy: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Cerebral Amyloid Angiopathy: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Cerebral Hemorrhage: chemically induced |2 MeSH |
| 650 | _ | 2 | |a Cerebral Hemorrhage: complications |2 MeSH |
| 650 | _ | 2 | |a Cerebral Hemorrhage: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Ischemic Stroke |2 MeSH |
| 650 | _ | 2 | |a Stroke: complications |2 MeSH |
| 700 | 1 | _ | |a Homeyer, P. |b 1 |
| 700 | 1 | _ | |a Haußmann, M. |b 2 |
| 700 | 1 | _ | |a Brandt, Daniel Moritz |0 P:(DE-2719)2812107 |b 3 |u dzne |
| 700 | 1 | _ | |a Donix, M. |0 P:(DE-2719)2501739 |b 4 |u dzne |
| 700 | 1 | _ | |a Puetz, V. |b 5 |
| 700 | 1 | _ | |a Linn, J. |b 6 |
| 773 | _ | _ | |a 10.1007/s00115-021-01206-w |0 PERI:(DE-600)1462945-8 |n 6 |p 599-604 |t Der Nervenarzt |v 93 |y 2022 |x 1433-0407 |
| 856 | 4 | _ | |u https://link.springer.com/article/10.1007%2Fs00115-021-01206-w |
| 856 | 4 | _ | |u https://pub.dzne.de/record/162912/files/DZNE-2021-01565.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/162912/files/DZNE-2021-01565.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:162912 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9000458 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 0 |6 P:(DE-2719)9000458 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2812107 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2501739 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NERVENARZT : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-01-28 |w ger |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-12 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1710008 |k AG Donix |l Clinical planning and intersite group |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1710008 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|